Bullboard - Stock Discussion Forum Cognition Therapeutics Inc CGTX

Healthcare

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular... see more

Add To Watchlist

NDAQ:CGTX - Post Discussion

Cognition Therapeutics Inc > Cognition Therapeutics Publishes EEG Findings from Phase 2 S

View:

Post by whytestocks on Aug 22, 2024 11:47am

Cognition Therapeutics Publishes EEG Findings from Phase 2 S

Breaking News: $CGTX Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's DiseasePURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of C...CGTX - Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease